Cleerly LABS vs Merlin.net

Cleerly LABS offers a rich diagnostic user experience with 3D visualization and an interactive web platform for in-depth review of complex CCTA data, providing clear actionable clinical insights for specialists. While Merlin.net focuses on streamlined workflow for remote monitoring, Cleerly's advanced visualization makes intricate diagnostic information more accessible and intuitive for its target users.

Cleerly LABS is FDA-cleared and provides comprehensive AI-powered analysis of CCTA to detect, quantify, and characterize atherosclerosis and stenosis, aiming to eliminate heart attacks by establishing a new standard of care focused on prevention. It has strong clinical validation, including studies comparing its plaque analysis to invasive imaging modalities and demonstrating high diagnostic accuracy and prognostic utility for ischemia detection. Merlin.net, also FDA-cleared, offers significant value in optimizing the management of patients with existing implanted cardiac devices, but Cleerly's potential for primary prevention and transformative impact on early disease management offers a higher clinical value proposition.

Cleerly LABS provides transparent pricing per analysis, with a retail price of $1500 and a discounted offer of $750, and has secured significant insurance coverage from major payers including Medicare, Aetna, and UnitedHealthcare, along with a dedicated CPT I code. [JSON, cite: 11, 27] This transparency and growing reimbursement support make its value more assessable and accessible. Merlin.net, in contrast, requires contacting the vendor for pricing, making it difficult to evaluate its value proposition without direct inquiry. [JSON]

Both tools are cloud-based, HIPAA compliant, FDA-cleared, and offer EHR integration. However, Merlin.net explicitly highlights its ISO 27001 certification and SOC 2 Type II report, demonstrating a robust commitment to cybersecurity and data protection. It also specifies compatibility with 'All HL7-compliant EHR systems' and lists several major EHRs, indicating broad and standardized integration capabilities.

Cleerly LABS represents a more significant innovation by leveraging AI for a novel, comprehensive, and quantitative assessment of coronary plaque and stenosis from CCTA, aiming to create a new standard of care for heart disease prevention. [JSON, cite: 9, 29] This shifts the paradigm from stenosis-centric to plaque-centric evaluation. Merlin.net's innovations focus on enhancing existing remote monitoring workflows for implanted devices with integrated features, which, while valuable, are less disruptive than Cleerly's approach to early diagnosis and risk stratification.

Abbott's Merlin.net provides comprehensive support resources, including detailed 'Manuals & Resources' such as a help manual for its application and an EHRDirectu2122 Integration FAQ, along with dedicated customer service contact information and 'Education & Training' materials. Cleerly LABS offers general support availability during business hours and a contact form, but lacks the explicit detail and breadth of documented resources found for Merlin.net.